---
title: Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in
  the St. Jude Total Therapy XV/XVI studies
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316653/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: Children with ETV6::RUNX1 or high-hyperdiploid B-acute lymphoblastic
  leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers
  these patients low-risk, regardless of their National Cancer Institute (NCI) risk,
  except when there is slow minimal residual disease (MRD) response or central nervous
  system/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years)
  with these genotypes in the SJ Total XV and XVI studies (2000-2017). Patients ...
disable_comments: true
---
Children with ETV6::RUNX1 or high-hyperdiploid B-acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low-risk, regardless of their National Cancer Institute (NCI) risk, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years) with these genotypes in the SJ Total XV and XVI studies (2000-2017). Patients ...